Patents by Inventor Yves Millet

Yves Millet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED BACTERIA EXPRESSING RACEMASE FOR TREATING DISEASES ASSOCIATED WITH HYPERAMMONEMIA
    Publication number: 20210130806
    Abstract: Disclosed herein are bacteria engineered to treat diseases associated with hyperammonemia and methods of use thereof. Specifically, the bacteria are engineered to comprise a racemase to enable the detection of non-naturally occurring metabolites as an indication that the engineered bacteria are effectively converting ammonia.
    Type: Application
    Filed: November 2, 2018
    Publication date: May 6, 2021
    Inventors: Yves Millet, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Dean Falb
  • Bacteria engineered to treat a disease or disorder
    Patent number: 10933102
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 2, 2021
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • Bacteria Engineered to Reduce Hyperphenylalaninemia
    Publication number: 20200246394
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Application
    Filed: February 12, 2020
    Publication date: August 6, 2020
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Sarah Rowe
  • BACTERIA FOR THE TREATMENT OF DISORDERS
    Publication number: 20200172857
    Abstract: Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.
    Type: Application
    Filed: June 21, 2018
    Publication date: June 4, 2020
    Inventors: Dean Falb, Adam B. Fisher, Vincent M. Isabella, Jonathan W. Kotula, David Lubkowicz, Paul F. Miller, Yves Millet, Sarah Elizabeth Rowe
  • Bacteria engineered to reduce hyperphenylalaninemia
    Patent number: 10610546
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: April 7, 2020
    Assignee: Synlogic Operating Company Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Sarah Rowe
  • MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS
    Publication number: 20190336544
    Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 7, 2019
    Applicants: Synlogic Operating Company, Inc., Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li, Jose M. Lora
  • BACTERIA ENGINEERED TO TREAT METABOLIC DISEASES
    Publication number: 20190298779
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
    Type: Application
    Filed: June 24, 2016
    Publication date: October 3, 2019
    Applicant: Synlogic Operating Company, Inc.
    Inventors: Dean FALB, Vincent M. ISABELLA, Jonathan W. KOTULA, Paul F. MILLER, Sarah ROWE, Yves MILLET, Adam FISHER
  • RECOMBINANT BACTERIA ENGINEERED TO TREAT DISEASES AND DISORDERS ASSOCIATED WITH AMINO ACID METABOLISM AND METHODS OF USE THEREOF
    Publication number: 20190282628
    Abstract: The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells that comprise an amino acid catabolism enzyme for the treatment of diseases and disorders associated with amino acid metabolism, including cancer, in a subject. The disclosure further provides pharmaceutical compositions and methods of treating disorders associated with amino acid metabolism, such as cancer.
    Type: Application
    Filed: January 11, 2017
    Publication date: September 19, 2019
    Inventors: Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Alex Tucker, Yves Millet, Adam B. Fisher
  • MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS
    Publication number: 20190160115
    Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
    Type: Application
    Filed: January 11, 2017
    Publication date: May 30, 2019
    Inventors: Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li
  • Bacteria engineered to reduce hyperphenylalaninemia
    Patent number: 10195234
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: February 5, 2019
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet
  • BACTERIA ENGINEERED TO TREAT METABOLIC DISEASES
    Publication number: 20190010506
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
    Type: Application
    Filed: December 28, 2016
    Publication date: January 10, 2019
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam B. Fisher, Sarah Elizabeth Rowe, Alex Tucker
  • BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL
    Publication number: 20180325963
    Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.
    Type: Application
    Filed: August 31, 2016
    Publication date: November 15, 2018
    Applicant: Synlogic, Inc.
    Inventors: Vincent Isabella, Dean Falb, Cami Leigh Anderson, Paul Miller, Yves Millet, Jonathan Kotula
  • BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA
    Publication number: 20180320161
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Application
    Filed: November 16, 2016
    Publication date: November 8, 2018
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet
  • Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tightened Gut Mucosal Barrier
    Publication number: 20180312851
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Application
    Filed: September 8, 2016
    Publication date: November 1, 2018
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
  • BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER
    Publication number: 20180280451
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Application
    Filed: December 22, 2017
    Publication date: October 4, 2018
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER
    Publication number: 20180169154
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Application
    Filed: December 22, 2017
    Publication date: June 21, 2018
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • Bacteria engineered to reduce hyperphenylalaninemia
    Patent number: 9943555
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: April 17, 2018
    Assignee: Synlogic, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Sarah Rowe
  • Bacteria engineered to treat a disease or disorder
    Patent number: 9889164
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: February 13, 2018
    Assignee: Synlogic, Inc.
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA
    Publication number: 20170312320
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Application
    Filed: May 13, 2016
    Publication date: November 2, 2017
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet
  • BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING THE CATABOLISM OF A BRANCHED CHAIN AMINO ACID
    Publication number: 20170232043
    Abstract: The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding a branched chain amino acid catabolism enzyme. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders involving the catabolism of branched chain amino acids using the pharmaceutical compositions disclosed herein.
    Type: Application
    Filed: December 14, 2016
    Publication date: August 17, 2017
    Inventors: Dean Falb, Paul F. Miller, Yves Millet, Vincent M. Isabella, Jonathan W. Kotula, Alex Tucker